Early Upward-Movers: GW Pharmaceuticals (GWPH), Caladrius Biosciences (CLBS)


Shares of GW Pharmaceuticals PLC (Nasdaq:GWPH) skyrocketed more than 100% in pre-market trading Monday after the company said that its cannabidiol Epidiolex achieved the primary endpoint in a late stage study by significantly reducing seizures in children with Dravet syndrome versus placebo

GWPH stock closed at $38.46, up $1.82 (or +4.97%), and 954,517 of its shares exchanged hands on the last trading session

GW Pharmaceuticals, which engages in discovering, developing, and commercializing cannabinoid prescription medicines, has 21.78M Shares Outstanding and GWPH stock 52-week range is between $35.83 and $133.98 per share. At close on Friday, the company had Market Capitalization of $837.77M



The price of Caladrius Biosciences, Inc. (Nasdaq:CLBS) stock surged over 20% before the market opened Monday as the company announced that Hitachi Chemical Co., Ltd. acquired a 19.9% stake in its subsidiary PCT, LLC for $19.4 million. According to Caladrius, Hitachi also will make an upfront and near term milestone payments of $5.6 million to PCT as part of a collaboration deal

Shares of Caladrius finished Friday’s market activity at $0.839, up $0.159 (or +23.4%)

Caladrius Biosciences, a leading cell therapy company, has 55.37M Shares Outstanding, Market Capitalization (intraday) of $46.46 million and CLBS stock one-year range is from $0.40 to $4.25 per share


Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. GalaxyStocks is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read full disclaimer at http://galaxystocks.com/disclaimer/